Denali Therapeutics Inc. (DNLI)
NASDAQ · Healthcare
Denali Therapeutics Inc. Revenue 2016–2025
Denali Therapeutics Inc. annual/quarterly revenue history and growth rate from 2016 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Denali Therapeutics Inc. revenue for the quarter ending September 30, 2024 was 0, a 100.00% decrease year-over-year.
- Denali Therapeutics Inc. revenue for the twelve months ending September 30, 2024 was 1.3 M, a 99.67% decrease year-over-year.
- Denali Therapeutics Inc. annual revenue for 2025 was 0.
- Denali Therapeutics Inc. annual revenue for 2024 was 0, a 100.00% decrease from 2023.
- Denali Therapeutics Inc. annual revenue for 2023 was 330.5 M, a 214.60% increase from 2022.
- Denali Therapeutics Inc. annual revenue for 2022 was 105.1 M.
Revenue
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Denali Therapeutics Inc. (DNLI) — Frequently Asked Questions
Denali Therapeutics Inc. (DNLI) is a publicly traded US company. It has a market capitalization of $3.56B. Explore DNLI's stock price, financial statements, earnings history, margins and key ratios below.
What is Denali Therapeutics Inc.'s market cap?
Denali Therapeutics Inc. (DNLI) has a market capitalization of $3.56B.
What is the DNLI stock price?
DNLI trades at $20.61 (-0.87% on the day).
Is DNLI profitable?
In fiscal 2025, Denali Therapeutics Inc. reported net income of -$513M.